{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spondyloarthritis%2C+Axial&page=2", "query": { "condition": "Spondyloarthritis, Axial", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Spondyloarthritis%2C+Axial&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T11:58:00.297Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01087762", "title": "Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondyloarthropathies" ], "interventions": [ { "name": "CZP 200 mg Q2W", "type": "BIOLOGICAL" }, { "name": "CZP 400 mg Q4W", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2010-03", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01087762" }, { "nct_id": "NCT02962479", "title": "Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Axial Spondyloarthritis", "Ankylosing Spondylitis" ], "interventions": [], "intervention_types": [], "sponsor": "Eyal Kedar", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2016-10", "completion_date": "2017-10", "has_results": false, "last_update_posted_date": "2016-11-11", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 1, "location_summary": "Potsdam, New York", "locations": [ { "city": "Potsdam", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02962479" }, { "nct_id": "NCT01786668", "title": "Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "Tofacitinib 2 mg", "type": "DRUG" }, { "name": "Tofacitinib 5 mg", "type": "DRUG" }, { "name": "Tofacitinib 10 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 208, "start_date": "2013-04", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2016-06-10", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 22, "location_summary": "Indian Wells, California • Palm Desert, California • Clearwater, Florida + 15 more", "locations": [ { "city": "Indian Wells", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01786668" }, { "nct_id": "NCT02154425", "title": "A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Axial Spondyloarthritis (AxSpA)", "Non-radiographic Evidence-AxSpA", "Ankylosing Spondylitis", "Crohn's Disease", "Psoriatic Arthritis", "Rheumatoid Arthritis" ], "interventions": [ { "name": "Breast milk sampling", "type": "PROCEDURE" }, { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "UCB BIOSCIENCES, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 17, "start_date": "2014-09", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2018-04-03", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 3, "location_summary": "Los Angeles, California • Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02154425" }, { "nct_id": "NCT02696785", "title": "A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondyloarthritis" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 341, "start_date": "2016-05-02", "completion_date": "2018-10-17", "has_results": true, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Huntington Beach, California • Palm Desert, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Palm Desert", "state": "California" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02696785" }, { "nct_id": "NCT02509026", "title": "Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 210, "start_date": "2015-09-24", "completion_date": "2019-09-06", "has_results": true, "last_update_posted_date": "2020-06-16", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 12, "location_summary": "Pensacola, Florida • Chicago, Illinois • Mineola, New York + 4 more", "locations": [ { "city": "Pensacola", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02509026" }, { "nct_id": "NCT01870284", "title": "Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "Ixekizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2014-07", "completion_date": "2018-04", "has_results": false, "last_update_posted_date": "2014-09-16", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 34, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Upland, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Upland", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Trumbull", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01870284" }, { "nct_id": "NCT03259074", "title": "Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "GP2017 (adalimumab biosimilar)", "type": "BIOLOGICAL" }, { "name": "AIN457 150 mg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 859, "start_date": "2017-11-30", "completion_date": "2021-11-29", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 19, "location_summary": "Mesa, Arizona • Escondido, California • La Mesa, California + 16 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03259074" }, { "nct_id": "NCT01209689", "title": "A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Spondylitis, Ankylosing" ], "interventions": [ { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2010-10", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2013-01-17", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 19, "location_summary": "Huntington Beach, California • Aventura, Florida • Miami, Florida + 16 more", "locations": [ { "city": "Huntington Beach", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01209689" }, { "nct_id": "NCT02552212", "title": "Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis", "Nonradiographic Axial Spondyloarthritis", "Nr-axSpA" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB BIOSCIENCES GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 317, "start_date": "2015-09", "completion_date": "2020-05", "has_results": true, "last_update_posted_date": "2022-08-18", "last_synced_at": "2026-07-24T11:58:00.297Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Desert", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02552212" } ] }